Vertex Pharmaceuticals (VRTX) Common Equity (2009 - 2026)

Vertex Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $19.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 17.37% year-over-year to $19.4 billion; the TTM figure through Mar 2026 stood at $19.4 billion (up 17.37% YoY), while the FY2025 annual figure was $18.7 billion, up 13.75% from the prior year.
• Common Equity for Q1 2026 stood at $19.4 billion, up from $18.7 billion in the prior quarter.
• The five-year high for Common Equity was $19.4 billion in Q1 2026, with the low at $10.9 billion in Q1 2022.
• The 5-year median for Common Equity is $16.4 billion (2024), against an average of $15.8 billion.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 37.75% in 2022, then fell 11.05% in 2025.
• Vertex Pharmaceuticals' Common Equity stood at $13.9 billion in 2022, then gained by 26.36% to $17.6 billion in 2023, then dropped by 6.66% to $16.4 billion in 2024, then rose by 13.75% to $18.7 billion in 2025, then climbed by 3.73% to $19.4 billion in 2026.
• Business Quant data shows VRTX's Common Equity at $19.4 billion in Q1 2026, $18.7 billion in Q4 2025, and $17.3 billion in Q3 2025.